Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
S Mailankody, JV Matous, S Chhabra, M Liedtke… - Nature medicine, 2023 - nature.com
ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …
Understanding the General Principles of T Cell Engagement by Multiscale Computational Simulations
The use of bispecific antibodies as T cell engagers can bypass the normal TCR-MHC
interaction, redirect the cytotoxic activity of T-cells, and lead to highly efficient tumor cell …
interaction, redirect the cytotoxic activity of T-cells, and lead to highly efficient tumor cell …
Gene therapy with B‐cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma
F Peng, Y Wang, J Zhao, H Liu, Z Liu… - British Journal of …, 2023 - Wiley Online Library
The delivery of bispecific antibodies (BsAbs) targeting B‐cell maturation antigen (BCMA)
and CD3 using the gene therapy approach is a promising alternative for BsAb administration …
and CD3 using the gene therapy approach is a promising alternative for BsAb administration …